Stockchase Opinions

Robert LauzonCVS Health CorpCVSBUYNov 22, 2018

He likes it. He bought it mid-year in a fund he manages. It is below what he paid now but represents pretty good value. They are going through a proposed merger which should be finalized by the end of the year. There are too many pharmacies out there. Pricing is also a headwind, as is food. They are doing a vertical integration with other health care companies. It is probably a $75-$105 stock. It is a defensive part of his portfolio. With the dividend it should make double digit returns. (Analysts’ price target is $92.00)
N/A

Stock price when the opinion was issued

$95.93

As of Jun 05, 2026. Market Open.

specialty stores
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

PAST TOP PICK
(A Top Pick Nov 28/23, Up 10%)

Bought at less than 10x earnings with recent dividend increase is good for share price appreciation. Recent M&A also good for investors. Will continue to own shares. Excellent management team and solid dividend. Weakness is sector creating opportunities to buyout competitors. 

BUY

Price target was raised today. This peaked in 2020-1 then was hit with a lot of bad news, like doubts over Signify and Oak Street acquisitions. But that negative sentiment has reversed, like their Medicare Advantage stars rating has gone up, and the street sees profitability rising in their pharmacy benefits management system, based on a new model last month. Trades under a cheap PE and pays a 3% dividend. He targets over $100 in 12 months. Is underloved and over-owned.

BUY

They just had a good investor day. If this breaks $76, it will rocket.

BUY ON WEAKNESS

Retail pharmacy chain business very strong. Largest health insurance plan very good business. Things stock is under valued. P/E lower than peers. Would recommend watching. Not buying at this time. Scored 8/10 on fundamentals. Expecting 30% upside. Good if recession occurs. 

TOP PICK

Healthcare has lagged this year. They run a chain of pharmacies, Aetna health insurance, pharmacy management and recently bought Oak Health. The CEO is doing a great job, and shares are not expensive around 8.5x PE. They took one some debt to bought some companies, but once they integrated them, it will ramp up cash flow.

(Analysts’ price target is $87.45)
DON'T BUY

Like many retailers, they struggle with theft. Home healthcare at these US chains was supposed to prosper, but it didn't. Low margins and low barriers to entry.

DON'T BUY

It is so large now and a conglomerate with many divisions. The big pharmacies like Walgreen and CVS are in some difficulty and staffs are worn out. There are better opportunities elsewhere.

PAST TOP PICK
(A Top Pick Jul 22/22, Down 23%)

Very large acquisition in health clinics. Pharmacy side of business struggling. Becoming a major healthcare provider in USA. Trading at 8x earnings. Cash flow excellent. Good for long term investors. Will continue to hold. Strong management team. 

BUY

Likes their diversity within US healthcare: insurance, pharmacy benefits and of course drug stores. They bought Signify and Oak Street which will be additive. CVS will definitely perform. Trades at a very low PE of under 8x and produces a ton of cash. Be patient with CVS.

PAST TOP PICK
(A Top Pick Sep 21/22, Down 26%)

Insider selling earlier this year. One of its insurers pulled back on commitments. Very strong brand in the US, one of the largest, which puts a moat around it. Aging population will need more healthcare. Too cheap to ignore right now.

PAST TOP PICK
(A Top Pick Dec 15/22, Down 26%)

Diversified into a vertically integrated healthcare colossus. Aetna business is weighing them down, but could be temporary. Compelling 8x earnings, very cheap, well capitalized, nice dividend. As long as Americans need healthcare, CVS will be part of that.

DON'T BUY

They can't control their theft problem.

BUY

Very positive on company.
Integrated healthcare company.
Demand for healthcare rising steadily.
Current share price under valued.
Good for long term investors.
Untapped franchise potential.
Expecting 10-12% share price growth.